

American Cancer Society and Break Through Cancer Unite to Outsmart Ovarian Cancer

In recognition of Ovarian Cancer Awareness Month, two leading cancer research organizations collaborate to bring decades of scientific research into clinical practice

September 29, 2025 By American Cancer Society

More than [20,000 new cases](#) of ovarian cancer will be diagnosed in the United States this year, and more than 12,000 women are expected to die from the disease. On September 25, the [American Cancer Society \(ACS\)](#) and [Break Through Cancer](#) announced a strategic collaboration that will aim to advance ovarian cancer awareness and prevention, as well as help to save lives. This alliance will turn two decades of scientific advances into action by combining research, education, awareness, marketing, and policy strategies to support those at risk of ovarian cancer and their clinicians.

“The Outsmart Ovarian Cancer campaign seeks to close the gap between science and practice to ensure that patients and health care providers know the facts, the options, and have the potential to stop ovarian cancer before it starts,” said [Dr. William Dahut](#), chief scientific officer of the American Cancer Society. “This awareness campaign aims to give everyone their best chance to outsmart ovarian cancer.”

For almost two decades, scientists have known that the majority of lethal ovarian cancers begin in the fallopian tubes. This discovery opened the door to new prevention strategies: opportunistic salpingectomy, or the surgical removal of fallopian tubes at the time of another surgical procedure. Opportunistic salpingectomy is a feasible and safe gynecologic practice that can reduce an individual patient’s ovarian cancer risk by up to 80%. Patients should consider the procedure instead of tubal ligation or at the time of hysterectomy or other abdominal and pelvic surgeries. Despite the availability of additional preventive interventions, critical lifesaving knowledge has yet to reach those who could most benefit.

Today, ACS and Break Through Cancer are determined to raise awareness of preventative interventions and turn science into action. Grounded in the latest research, this initiative will focus on raising awareness about the origins of ovarian cancer and giving people strategies to reduce the risk of developing the disease, the sixth most common cause of cancer deaths for women in the U.S.

“With the American Cancer Society’s national platform and Break Through Cancer’s scientific engine, we are joining forces to bring this knowledge to millions of women,” said Tyler Jacks, president of Break Through Cancer. “The Outsmart Ovarian Cancer campaign is poised to share emerging research, inform patients, and support health care providers with resources and evolving prevention strategies.”

From Research to Policy to Practice

The Outsmart Ovarian Cancer campaign is grounded in years of multi-institutional research in the United States and around the world. The campaign specifically builds on recent efforts by Rebecca Stone, MD, at Johns Hopkins Kimmel Cancer Center and Kara Long, MD, from the Memorial Sloan Kettering Cancer Center. In 2022, Break Through Cancer launched the Intercepting Ovarian Cancer TeamLab, a scientific collaboration uniting researchers and clinicians from five of the nation’s top cancer centers: Johns Hopkins Kimmel Cancer Center, Dana-Farber Cancer Institute, MIT’s Koch Institute for Integrative Cancer Research, Memorial Sloan Kettering Cancer Center, and the University of Texas MD Anderson Cancer Center to tackle ovarian cancer through radical collaboration.

TeamLab has advanced early detection science, launched clinical studies, and achieved a major policy milestone: helping to establish a new ICD-10 encounter code for opportunistic salpingectomy, an important step toward making the procedure a recognized, reimbursable, and trackable standard of care.

Additional Resources:

- [About Ovarian Cancer](#)
- [Ovarian Cancer – Causes, Risk Factors & Prevention](#)
- [Cancer Statistics, 2025](#)
- [Cancer Risk 360 Screening Tool](#)

[This press release](#) was originally published September 25, 2025, by the American Cancer Society. It is republished with permission.